Editorial: New advancement in tumor microenvironment remodeling and cancer therapy

Editorial: New advancement in tumor microenvironment remodeling and cancer therapy

Bibliographic Details
Main Authors:	Yi Yao, Ying Shen, James C. Yao, Xiangsheng Zuo
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-03-01
Series:	Frontiers in Cell and Developmental Biology
Subjects:	TME cancer therapeutics immune check inhibitor PD-L1 tumor mutational burden
Online Access:	https://www.frontiersin.org/articles/10.3389/fcell.2024.1384567/full

Similar Items

Beyond PD-L1 Markers for Lung Cancer Immunotherapy
by: Kamila Wojas-Krawczyk, et al.
Published: (2019-04-01)

The Immune Microenvironment in Penile Cancer and Rationale for Immunotherapy
by: Mohamed E. Ahmed, et al.
Published: (2020-10-01)

Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities
by: Antonio Santaniello, et al.
Published: (2019-09-01)

Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target
by: Conner Hartupee, et al.
Published: (2024-02-01)

Editorial: Tumor microenvironment immunophenotypes and disease progression
by: Ana Carolina Monteiro, et al.
Published: (2023-01-01)

Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer
by: Sarah Sammons, et al.
Published: (2023-08-01)

Challenges and Future Directions in the Management of Tumor Mutational Burden-High (TMB-H) Advanced Solid Malignancies
by: Jibran Ahmed, et al.
Published: (2023-12-01)

The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors
by: Camille Moeckel, et al.
Published: (2023-04-01)

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer
by: Man Wang, et al.
Published: (2023-02-01)

Tumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and Opportunities
by: Romualdo Barroso-Sousa, et al.
Published: (2023-08-01)

Visualization of the Effect of Assay Size on the Error Profile of Tumor Mutational Burden Measurement
by: Nathanael G. Bailey
Published: (2022-02-01)

Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse Gliomas
by: Guangyang Yu, et al.
Published: (2021-12-01)

Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors
by: Yu Chen, et al.
Published: (2020-09-01)

SETD2 variation correlates with tumor mutational burden and MSI along with improved response to immunotherapy
by: Xiaobin Zheng, et al.
Published: (2023-07-01)

Lipid metabolic features of T cells in the Tumor Microenvironment
by: Wanshuang Lou, et al.
Published: (2022-10-01)

Interaction between tumor microenvironment, autophagy, and epithelial-mesenchymal transition in tumor progression
by: Wen-Ming Wang, et al.
Published: (2022-01-01)

Interplay between Tumor Mutational Burden and Mutational Profile and Its Effect on Overall Survival: A Pilot Study of Metastatic Patients Treated with Immune Checkpoint Inhibitors
by: Camila B. Xavier, et al.
Published: (2022-11-01)

Editorial: Molecular targeting of the tumor microenvironment for therapeutics in cancer metastasis
by: Subramanyam Dasari, et al.
Published: (2023-03-01)

Editorial: Anti-cancer effects of botanical drugs targeting the tumor microenvironment
by: Chien-shan Cheng, et al.
Published: (2023-08-01)

POLE/POLD1 mutation and tumor immunotherapy
by: Xiaoting Ma, et al.
Published: (2022-07-01)

LSD1: an emerging face in altering the tumor microenvironment and enhancing immune checkpoint therapy
by: M A A Mamun, et al.
Published: (2023-07-01)

Defining Tumor Microenvironment as a Possible Target for Effective GEP-NENs Immunotherapy—A Systematic Review
by: Paulina Chmiel, et al.
Published: (2023-10-01)

Complete and Durable Response to Nivolumab in Recurrent Poorly Differentiated Pancreatic Neuroendocrine Carcinoma with High Tumor Mutational Burden
by: Nai-Wen Kang, et al.
Published: (2021-11-01)

Relationship between tumor mutational burden, gene mutation status, and clinical characteristics in 340 cases of lung adenocarcinoma
by: Kai Ma, et al.
Published: (2022-11-01)

Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
by: Jong Yeob Kim, et al.
Published: (2019-11-01)

Editorial: Tumor microenvironment in bladder cancer
by: Sergei Kusmartsev, et al.
Published: (2023-05-01)

Rare Combined Small Cell Lung Carcinoma and Lung Squamous Cell Carcinoma Response to PD-1 Inhibitor as Third-Line Therapy: A Case Report
by: Liu Z, et al.
Published: (2023-02-01)

Editorial: The roles of immune cell homeostasis in cancer research and therapeutic response
by: Kui Zhang, et al.
Published: (2023-06-01)

Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient
by: Giovanni Rossi, et al.
Published: (2020-04-01)

The Evolution of Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
by: Hélène Houssiau, et al.
Published: (2022-03-01)

A novel RNA modification prognostic signature for predicting the characteristics of the tumor microenvironment in gastric cancer
by: Qiangan Jing, et al.
Published: (2023-02-01)

Innate immune cells: Key players of orchestra in modulating tumor microenvironment (TME)
by: Mahvash Sadeghi, et al.
Published: (2024-03-01)

Editorial: Cell network in antitumor immunity of pediatric and adult solid tumors
by: Silvia Pesce, et al.
Published: (2023-07-01)

Oncolytic virus oHSV2 combined with PD-1/PD-L1 inhibitors exert antitumor activity by mediating CD4 + T and CD8 + T cell infiltration in the lymphoma tumor microenvironment
by: Jingbo Zhang, et al.
Published: (2023-12-01)

Dual antitumor immunomodulatory effects of PARP inhibitor on the tumor microenvironment: A counterbalance between anti-tumor and pro-tumor
by: Xiao-Fang Yi, et al.
Published: (2023-07-01)

Immune regulation and the tumor microenvironment in anti-PD-1/PDL-1 and anti-CTLA-4 therapies for cancer immune evasion: A bibliometric analysis
by: Yi Huang, et al.
Published: (2024-12-01)

Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction
by: Shixiang Wang, et al.
Published: (2019-11-01)

Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation
by: Bo Zhang, et al.
Published: (2022-09-01)

Comprehensive genomic analysis of primary bone sarcomas reveals different genetic patterns compared with soft tissue sarcomas
by: Qing Zhang, et al.
Published: (2023-07-01)

Multiple influence of immune cells in the bone metastatic cancer microenvironment on tumors
by: Shixin Chen, et al.
Published: (2024-02-01)